Please login to the form below

Not currently logged in
Email:
Password:

isavuconazole

This page shows the latest isavuconazole news and features for those working in and with pharma, biotech and healthcare.

Basilea bags $72m upfront from Pfizer for antifungal license

Basilea bags $72m upfront from Pfizer for antifungal license

Cresemba (isavuconazole) was approved in 2015 in both intravenous and oral formulations to treat adults with invasive aspergillosis and invasive mucormycosis, two life-threatening fungal infections typically seen in immunocompromised patients

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    We have also signed a deal with Basilea for Isavuconazole. In oncology, we've entered an agreement with AVEO Pharmaceuticals to commercialise and develop tivozanib, which has significant potential in a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics